THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

Saved in:
Bibliographic Details
Published in:Hematological oncology 2017-06, Vol.35 (S2), p.74-74
Main Authors: Hamlin, P.A., Farber, C.M., Fenske, T.S., Khatcheressian, J.L., Miller, C.B., Munoz, J., Patel, M.R., Schreeder, M.T., Smith, S.M., Stevens, D.A., Pandey, A., Birrell, M.R., Leeds, J.M., Wang, Y.L., Coffey, G.P., Curnutte, J.T.
Format: Article
Language:English
Subjects:
Inhibitors
Lymphocytes B
Patients
Syk protein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2437_61